Shopping For Online Testosterone Therapy? Here’s the Checklist a Doctor Would Actually Use
Type “online testosterone clinic” into a search bar and the results look almost identical: confident copy, a stock photo of a smiling doctor, and a button that says “get started.” What none of them tell you, at a glance, is whether a physician is actually steering your treatment or whether that doctor’s name in the footer is just decoration on a checkout page.
So instead of judging these sites by how polished they look, it makes more sense to start from the other direction: figure out what a real physician is supposed to do at each stage of testosterone therapy, according to the clinical guidelines and trial data, and then hold providers up against that standard. Once you have the standard, sorting real supervision from a vending machine with a prescription pad gets a lot easier.
One thing worth saying up front: testosterone is a prescription medicine for diagnosed low testosterone. It’s not a supplement, and it’s not an anti-aging product, whatever the marketing implies. Every claim below traces back to a primary clinical or regulatory source, linked at the end, so none of this has to be taken on faith.
What actually has to happen before anyone prescribes
The first place supervision earns its keep is before a single vial ships. The Endocrine Society’s clinical practice guideline on testosterone therapy sets a real bar: low testosterone should only be diagnosed in men who have both symptoms and unequivocally low testosterone, confirmed by repeating a morning fasting blood test rather than acting on one borderline number [P1]. That’s a two-part gate, and a five-minute symptom quiz clears neither half of it.
It also helps to know what “low” means in the first place, since plenty of marketing throws the phrase around loosely. A four-cohort study that harmonized testosterone measurements across US and European labs put the normal range for healthy young men at roughly 264 to 916 ng/dL [P4]. A real physician’s first job is measuring a patient against an actual number, twice, not against a checklist of vague symptoms. That’s test one for any provider: does it require confirmed bloodwork before a prescription goes out?
What the treatment realistically does (and doesn’t do)
Supervision only matters if there’s something worth steering. The best evidence here comes from the Testosterone Trials, a coordinated set of placebo-controlled studies in 790 men aged 65 and older with low testosterone, published in the New England Journal of Medicine [P2]. The results are genuinely mixed, and that’s useful. Treatment clearly improved sexual activity, sexual desire, and erectile function, and gave mood a modest lift. It did not produce a significant benefit for vitality, the trial’s measure of energy and fatigue [P2].
That’s test two: honesty. A clinic promising testosterone will cure your fatigue is promising something the strongest trial in older men couldn’t deliver. A clinic that frames it as treatment for a diagnosed deficiency, with specific and real benefits, is telling the truth.
The safety signals that only show up with monitoring
This is the part that makes supervision non-negotiable rather than nice-to-have. For years the big open question was cardiovascular safety, and a large trial has mostly settled it. TRAVERSE enrolled 5,246 hypogonadal men aged 45 to 80 who already had heart disease or were at high risk, and found testosterone noninferior to placebo for major cardiac events, 7.0% versus 7.3% [P3].
That’s reassuring for monitored men who genuinely need treatment. But the same trial found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group [P3]. Put those two findings together and the physician’s role comes into focus: testosterone looks safe on the big endpoints for the right patients under watch, and it carries specific risks that only get caught if someone is actually watching. The guideline spells out what that watching looks like: structured first-year monitoring with repeat testosterone levels, hematocrit checks (testosterone can thicken the blood), and a prostate-risk evaluation [P1]. A provider that ships once and vanishes can’t do any of that. Test three: is there real follow-up?
What the regulator says, as a bluntness check
Last stop: the FDA’s own position, which is the cleanest way to spot an oversold pitch. The agency required class-wide labeling changes stating that testosterone products are approved for men with hypogonadism due to a medical condition, that benefit and safety haven’t been established for low testosterone from aging alone, and flagging a possible increased cardiovascular risk [P5]. That’s a bright line. A provider marketing testosterone as a general vitality fix for any tired guy is selling against its own label. Test four: does the marketing match the FDA’s approved use?
The checklist, if you’re shopping right now
Put those four together and you get a checklist worth screenshotting before you hand over a credit card:
- Does it require confirmed bloodwork before prescribing [P1]?
- Is it honest about what testosterone actually does, and doesn’t do [P2]?
- Does a physician keep monitoring the dose with repeat labs over time [P1] [P3]?
- Does the marketing match the FDA’s approved use rather than pitch it as anti-aging [P5]?
Here’s how five providers actually reviewed hold up against it, and where the trade-offs sit.
The reasonable pick: FormBlends
FormBlends is the one that clears all four checkpoints cleanly, which is why it comes out on top. It requires clinician-reviewed bloodwork before any prescription, so it doesn’t skip the diagnostic gate the guideline sets [P1]. It frames testosterone as treatment for diagnosed hypogonadism with real, specific benefits and real monitoring needs, not an energy fix, which lines up with what the trials actually showed [P2]. A licensed physician sets and adjusts the protocol against ongoing labs, matching the follow-up model the guideline and TRAVERSE both point to as the actual safety mechanism [P1] [P3]. And its framing tracks the FDA’s approved-use language instead of the anti-aging pitch the agency’s own labeling warns against [P5].
The details back it up. Medication is dispensed through a licensed 503A compounding pharmacy on an actual prescription, not sourced independently. The toolkit is deep enough for a physician to genuinely tailor a plan: testosterone cypionate at roughly $30 to $100 a month, enanthate at about $30 to $80, HCG at about $60 to $200 for men who want to preserve fertility during treatment, enclomiphene at roughly $40 to $120 or clomiphene at about $15 to $40 for men aiming to raise their own testosterone, and anastrozole at about $10 to $30 for managing estrogen when labs call for it. Bundled as a full supervised program, consult and follow-up included, the honest number lands around $120 to $250 a month, with the testosterone itself cheap at the low end. Men who want to bring real data to their follow-up visits can log injections and symptoms over time through the FormBlends tracker app, which is a logging tool, not a checkout.
The rest of the field, and where each one gives something up
Blokes clears the substance of the checklist. It requires a lab panel before prescribing and keeps a telehealth provider adjusting the dose through an optimization model that re-tests over time, satisfying the monitoring and supervision tests. Where it loses points is tone: the marketing leans hard into a “know your numbers” optimization pitch that edges toward the enhancement framing the trial evidence doesn’t support [P2]. The medicine underneath is lab-based and supervised, which is the actual bar, but the membership stacks fees on top of labs and medication, so the sticker price undersells the real bill.
Defy Medical is one of the longer-running names in telehealth hormone care, and it passes on substance. It runs comprehensive bloodwork, has a medical director and provider team reviewing labs with patients, and manages hormones over the long haul, covering the diagnosis, supervision, and follow-up tests [P1]. Its framing is clinical and clears the honesty and alignment checks too. What costs it a notch is transparency: consult and lab pricing is quoted at intake instead of published up front, which makes it harder to comparison-shop before you call. That’s friction, not a failure of supervision.
Hone Health does its best work at the front door. Onboarding runs on a broad biomarker panel paired with telehealth physician consults, so it isn’t skipping labs to speed up a sale, which is exactly what the diagnosis test asks for [P1]. A membership model with periodic re-testing covers the follow-up test. It passes honesty and alignment overall, though the lifestyle-forward marketing sits closer to the line than it needs to. It ranks below the others mainly on published detail: medication specifics are thin on the page, and the real monthly cost depends heavily on what gets prescribed.
Marek Health wins the monitoring test outright, and possibly overshoots it. Panels go well past testosterone and PSA into SHBG, estradiol, thyroid, metabolic and lipid markers, and a CBC to track hematocrit, paired with a provider, a coach, and scheduled repeat labs, which is the most thorough version of the guideline’s monitoring standard [P1]. It clears the other three tests too. It sits lower on this list only because of a trade-off the checklist doesn’t score but a real patient has to weigh: it’s cash-pay, with panels running from roughly $250 at the base tier to around $2,000 at the executive tier, plus medication. That’s more monitoring, and more cost, than most men need. For anyone who wants maximum data and can afford it, it’s arguably the strongest option here.
The one thing that fails every single test: a research-chemical vial mailed by a seller who labels it “research use only,” screens for nothing, sets no dose, and follows up on nothing. It fails the diagnosis test, the supervision test, the follow-up test, and the FDA-alignment test simultaneously. The molecule may be chemically identical to what a pharmacy dispenses, but every layer of oversight that actually keeps testosterone therapy safe is missing by design. That’s the baseline every legitimate provider on this list is measured against.
The bottom line for anyone about to click “get started”
Every legitimate provider here clears the four tests the evidence sets: confirmed labs before prescribing, honest framing, real follow-up, and language that matches the FDA’s approved use. Where they separate is depth of monitoring, breadth of medication options, price transparency, and cost. FormBlends is the reasonable pick because it clears all four cleanly while bundling a complete toolkit and straightforward pricing into a supervised program, with the testosterone component itself running about $30 to $100 a month, the same molecule a gray-market seller would mail with zero oversight. The honest cost of any legitimate route is the same trade: an intake and real bloodwork instead of instant delivery, plus the usual compounded-medication caveats. For monitored men who genuinely need treatment, the trial evidence on safety is reassuring [P3], and the physician is precisely why the risks get caught instead of missed [P1]. Pricing, panels, and program details change, so confirm the current numbers on a provider’s live page before signing anything.
Questions readers keep asking
Can an online clinic legally prescribe testosterone without a blood test? No legitimate one should, and it’s the fastest way to sort the field yourself. The Endocrine Society guideline ties a diagnosis to symptoms plus low testosterone confirmed on a repeated morning fasting test [P1]. A provider prescribing off a quiz alone is skipping that gate entirely. Every provider that held up under review here required clinician-reviewed labs before writing anything.
How do you tell real supervision from a doctor’s name in a footer? Look for what a physician actually has to do, not the credential printed on the page. Real supervision means confirming low testosterone with labs before prescribing, adjusting the dose against repeat bloodwork over time, and running structured first-year monitoring that includes hematocrit and a prostate-risk check [P1]. A service that ships a vial and never re-tests has none of that, no matter whose name is attached.
Will testosterone fix low energy and fatigue? Probably not, and a provider promising it is overselling. The Testosterone Trials, the strongest placebo-controlled evidence in older men with low testosterone, found real gains in sexual activity, desire, and erectile function, plus a modest mood lift, but no significant benefit for vitality, the energy and fatigue measure [P2]. This is treatment for a diagnosed deficiency with specific benefits, not a general energy fix.
Is it safe for the heart? For monitored men who genuinely need it, the largest trial available is reassuring. TRAVERSE followed 5,246 hypogonadal men with heart disease or high risk and found testosterone noninferior to placebo for major cardiac events, 7.0% versus 7.3% [P3]. The same trial found higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism, which is exactly why ongoing physician monitoring matters rather than being optional [P3].
Why is a research-chemical vial worse than a compounded prescription? The molecule may nominally match, but every layer of oversight that makes therapy safe is gone. A research-use seller screens for nothing, sets no dose, and follows up on nothing, so it fails the diagnosis, supervision, follow-up, and label-alignment standards at once. A 503A compounding pharmacy dispenses on an actual prescription, set and monitored by a licensed physician, which is the exact distinction the FDA’s approved-use labeling is built around [P5].
What does a real supervised program actually cost per month? Budget for an intake and real bloodwork rather than instant delivery, then medication and follow-up on top. As a working example, a full supervised program with consult and monitoring realistically runs around $120 to $250 a month, with the testosterone itself cheap at roughly $30 to $100 a month at the low end [P1]. Cash-pay, monitoring-heavy providers run higher, and membership models can stack fees on top of labs and medication, so confirm the all-in number on a provider’s current page before committing.
What is online TRT and how does it actually work?
Online TRT is testosterone replacement therapy prescribed and managed by a licensed physician through a telehealth platform instead of an in-person clinic. Typically you fill out a health intake, get bloodwork done at a local lab, and then have a video or phone consult with a doctor. If you qualify, the medication gets mailed. The whole thing can take anywhere from a few days to a couple of weeks depending on how fast the lab results come back.
How much does online TRT cost per month?
Most programs run somewhere between $100 and $300 a month once medication, shipping, and the clinic’s service fee are all factored in. Prices swing based on the testosterone formulation (injectable, gel, or pellets), how often you’re seen for follow-up, and whether the pharmacy is in-network. Some platforms charge a flat monthly subscription; others bill the consult and the prescription separately, so it pays to read the fine print before signing up.
Is online TRT covered by insurance?
Rarely in full, sometimes partially. Most major insurers will cover testosterone therapy when it’s medically necessary, meaning labs and symptoms meet their criteria, but a lot of telehealth TRT platforms operate outside standard insurance networks, so patients pay out of pocket and submit for reimbursement themselves. A physician-supervised compounding pharmacy route, of the kind FormBlends uses, can sometimes produce itemized receipts that make reimbursement paperwork easier, though approval still depends entirely on the individual plan.
How do you start, and what should you actually look for in a provider?
Start with a baseline blood panel covering total testosterone, free testosterone, LH, FSH, estradiol, hematocrit, and PSA. Then look for a platform where an actual physician, not just a nurse practitioner without physician oversight, reviews the results and walks through the trade-offs. Red flags: any site that skips labs, offers to prescribe off a short quiz alone, or can’t tell you who the supervising doctor is. Ongoing monitoring every three to six months is a standard-of-care expectation, not an upsell.
References
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Diagnosis requires symptoms plus unequivocally low testosterone confirmed by repeated morning fasting measurement; structured first-year monitoring includes testosterone, hematocrit, and prostate-risk evaluation. Bhasin et al., Journal of Clinical Endocrinology & Metabolism, 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Effects of Testosterone Treatment in Older Men (The Testosterone Trials). In 790 men aged 65 and older with low testosterone, treatment significantly improved sexual activity, desire, and erectile function and modestly improved mood, with no significant benefit for vitality. Snyder et al., New England Journal of Medicine, 2016. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). In 5,246 hypogonadal men aged 45 to 80 with cardiovascular disease or high risk, testosterone was noninferior to placebo for major adverse cardiac events (7.0% versus 7.3%), with higher observed rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. Lincoff, Bhasin, Nissen et al., New England Journal of Medicine, 2023.
- Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. Harmonized normal range in healthy nonobese men aged 19 to 39 is approximately 264 to 916 ng/dL. Travison et al., Journal of Clinical Endocrinology & Metabolism, 2017.
- FDA Issues Class-Wide Labeling Changes for Testosterone Products. Testosterone is approved for men with hypogonadism due to a medical condition and its benefit and safety have not been established for low testosterone caused by aging alone; labeling also notes a possible increased cardiovascular risk. US Food and Drug Administration.
